Senior Vice President - NYBCe, Comprehensive Cell Solutions

About the role

The SVP of CCS will be responsible for providing strategic leadership and direction to the business unit, ensuring operational excellence, financial growth, and a competitive edge in the cell and gene therapy market.

Strategic Leadership And Vision

• Develop and execute the business unit’s long-term vision, strategy, and business plan, focusing on growth in the cell and gene therapy space.
• Stay ahead of industry trends, scientific advancements, and regulatory changes affecting CCS and biopharma industries.
• Ensure alignment with the Enterprise’s mission of providing top-tier draw-to-thaw services for cell and gene therapy customers.

Operational Excellence

• Oversee CCS’ operations, ensuring the company delivers high-quality, scalable solutions for clients.
• Lead efforts and high-performing teams to continuously improve operational processes, efficiency, and compliance with regulatory standards (e.g., GMP, FDA, EMA), accrediting organizations (e.g., FACT) and industry best practices.
• Drive innovation in cell and gene therapy technologies, improving and adopting new development and manufacturing capabilities.

Client And Partner Relations

• Build and maintain strong relationships with existing and potential clients, identifying opportunities for growth and collaboration.
• Ensure high client satisfaction through delivering products on time, maintaining quality standards, and optimizing client experience.
• Foster partnerships with key stakeholders in hospitals/institutions, biotech, pharmaceutical companies, industry associations, and regulatory bodies.

Financial Performance And Growth/Business Development

• Develop financial, key performance indicators and business development strategies to drive growth, increase revenue, and optimize profitability while managing risk.
• Oversee budgeting, financial planning, pricing strategies, and forecasting, ensuring the business unit meets or exceeds revenue and EBITDA targets.
• Work with CEO and CFO to secure funding for expansion, technological advancements, and growth initiatives.

Risk Management

• Assess and manage the department’s risks, including operational, financial, regulatory, and market risks, ensuring that adequate safeguards are in place.
• Implement and oversee crisis management strategies, ensuring business continuity and resilience in response to unforeseen challenges.

Education Qualifications

• Advanced degree in life sciences, biotechnology, biochemistry or a related field.
• Minimum of 15 years of senior leadership experience 3-5 years in an executive leadership role within a biotechnology, pharmaceutical, or CDMO environment.
• Proven track record in the development, manufacturing, and/or commercialization of cell and gene therapies.
• Experienced managing internal and external customers and stakeholders.

Travel Ability

• To travel 25% to NYBCe locations.

Knowledge

• Strong understanding of GMP, FDA/EMA regulations, and compliance frameworks in cell and gene therapy.

Skills

• Cultural competency and the ability to communicate effectively in a culturally sensitive manner with both individuals and groups from diverse backgrounds.
• Exceptional leadership and team-building skills, with the ability to inspire and manage diverse teams, including organized labor groups.
• Strong financial acumen, with experience in managing a P&L.
• Outstanding oral and written communication and interpersonal skills, with the ability to engage with clients, partners, investors, and regulatory bodies.
• Deep technical understanding of apheresis, cell and gene therapy development and manufacturing processes.

Abilities

• Strategic thinker with the ability to execute and drive business growth in a highly competitive and regulated market.

Overview

Founded in 1964, New York Blood Center (NYBC) has served the tri-state area for more than 60 years, delivering 500,000 lifesaving blood products annually to 150+ hospitals, EMS and healthcare partners. NYBC is part of New York Blood Center Enterprises (NYBCe) , which spans 17+ states and delivers one million blood products to 400+ U.S. hospitals annually. NYBCe additionally delivers cellular therapies, specialty pharmacy, and medical services to 200+ research, academic and biopharmaceutical organizations. NYBCe’s Lindsley F. Kimball Research Institute is a leader in hematology and transfusion medicine research, dedicated to the study, prevention, treatment and cure of bloodborne and blood-related diseases. NYBC serves as a vital community lifeline dedicated to helping patients and advancing global public health. To learn more, visit nybc.org . Connect with us on Facebook , X , Instagram , and LinkedIn .